Ironwood Pharmaceuticals Inc (IRWD)

15.71
0.29 1.90
NASDAQ : Health Care
Prev Close 15.42
Open 15.43
Day Low/High 15.29 / 15.62
52 Wk Low/High 7.35 / 14.35
Volume 283.82K
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 149.59M
Market Cap 2.27B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ironwood Pharmaceuticals Stock Sees Short Interest Move 16% Higher

Ironwood Pharmaceuticals Stock Sees Short Interest Move 16% Higher

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 2,249,386 share increase in total short interest for Ironwood Pharmaceuticals Inc , to 16,348,161, an increase of 15.95% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

The Cambridge, Mass.-based firm clinched FDA approval for hyperuricemia drug Duzallo.

DUZALLO(R) (lesinurad And Allopurinol) (Photo: Business Wire)

DUZALLO(R) (lesinurad And Allopurinol) (Photo: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced DUZALLO was approved by the U.

Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its second quarter 2017 results and recent business activities.

Ironwood Pharmaceuticals To Host Second Quarter 2017 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2017 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2017 investor update conference call and webcast at 4:30 p.

Ironwood Pharmaceuticals Reports Positive Top-line Results From IW-3718 Phase IIb Trial In Uncontrolled Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals Reports Positive Top-line Results From IW-3718 Phase IIb Trial In Uncontrolled Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, announced positive top-line data from a Phase IIb clinical trial evaluating IW-3718 in adult patients with uncontrolled...

Ironwood Pharmaceuticals To Present At The Goldman Sachs 38th Annual Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 38 th Annual Global Healthcare Conference on Thursday, June 15, 2017 at 10:00 a.

Ironwood Pharmaceuticals To Present At The Jefferies Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies Healthcare Conference on Thursday, June 8, 2017 at 4:00 p.

Ironwood Pharmaceuticals To Present At The Bank Of America Merrill Lynch Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 17, 2017 at 1:00 p.

Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect On Pain At Digestive Disease Week® 2017

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, this week presented clinical data on the effect of linaclotide on abdominal pain in irritable bowel syndrome with constipation (IBS-C)...

Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, today provided an update on its first quarter 2017 results and recent business activities.

Ironwood Pharmaceuticals To Present New Data For Linaclotide, Linaclotide Delayed Release And IW-1701 At Digestive Disease Week® 2017

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company and its collaborators will present clinical and preclinical data for linaclotide and linaclotide...

First Week of IRWD June 16th Options Trading

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the June 16th expiration.

Ironwood Pharmaceuticals To Host First Quarter 2017 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2017 investor update conference call and webcast at 8:30 a.

Ironwood Pharmaceuticals Appoints Dr. Christopher Wright As Senior Vice President Of Global Development And Chief Development Officer

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the appointment of Christopher Wright, M.

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 16, 2017 at 10:45 a.

Ironwood Pharmaceuticals Showcases Progress Delivering Innovative Medicines To Patients And Building A Top-Performing Commercial Biotech At R&D Day 2017

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, is hosting an R&D Day today, Thursday, March 9, 2017, beginning at 9:00 a.

Ironwood Pharmaceuticals To Present At Cowen And Company 37th Annual Health Care Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Cowen and Company 37 th Annual Health Care Conference on Monday, March 6, 2017 at 2:00 p.

Ironwood Pharmaceuticals To Host R&D Day On March 9, 2017

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will host a live webcast of its R&D Day on Thursday, March 9, 2017 beginning at 9:00 a.

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2016 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2016 results and recent business activities.

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Ironwood Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Ironwood Pharmaceuticals Inc. have crossed above the average analyst 12-month target price of $16.25, changing hands for $16.38/share.

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2016 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2016 investor update conference call and webcast at 4:30 p.

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday.

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

New bowel drug Trulance will be available for patients later this quarter.

Ironwood Pharmaceuticals Demonstrates Strong Execution On Strategy To Build Top-Performing Commercial Biotech

Ironwood Pharmaceuticals Demonstrates Strong Execution On Strategy To Build Top-Performing Commercial Biotech

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today detailed strong execution against its strategy of building a top-performing commercial biotechnology company generating rapid, sustainable, high-margin growth.

Ironwood Pharmaceuticals Appoints Amy Schulman To Board Of Directors

Ironwood Pharmaceuticals Appoints Amy Schulman To Board Of Directors

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the appointment of Amy Schulman to its board of directors.

TheStreet Quant Rating: D (Sell)